Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

BRIEF-Aralez reports reduction in U.S. sales force

Published 2017-04-05, 07:04 a/m
© Reuters.  BRIEF-Aralez reports reduction in U.S. sales force
ARLZQ
-

April 5 (Reuters) - Aralez Pharmaceuticals Inc ARZ.TO :

* Aralez announces reduction in U.S. Sales force and cost savings program

* Aralez Pharmaceuticals Inc - 32 pct reduction in U.S. sales force

* Aralez Pharmaceuticals Inc - reduction in sales force is expected to reduce current annual run rate of operating expenses by approximately $7.5 million

* Aralez Pharmaceuticals Inc - sales force restructuring is expected to yield savings for 2017 and beyond

* Aralez Pharmaceuticals Inc - strategic realignment of resources with an emphasis on zontivity launch

* Aralez Pharmaceuticals says as a result of sales force reduction, anticipates it will incur cash severance costs of approximately $0.6 million in q2 of 2017

* Aralez Pharmaceuticals Inc - company intends to communicate details of the plan in its q1 2017 earnings release to be issued in early may 2017

* Aralez Pharma- plan includes realignment of certain financial resources to support phased launch of zontivity that is expected to begin in mid-april

* Aralez Pharmaceuticals Inc says is in process of finalizing its overall cost savings plan

* Aralez Pharmaceuticals Inc - cost savings plan includes significant decrease in marketing spend on yosprala

* Aralez Pharma-has begun other initiatives expected to reduce spending across business, some of which were already assumed in previously issued financial guidance Source text for Eikon: ID:nCNWZZ3lka Further company coverage: ARZ.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.